Tumour endoprostheses have facilitated limb-salvage procedures in primary bone and soft tissue sarcomas, and are increasingly being used in symptomatic metastases of the long bones.

The objective of the present review was to analyse articles published over the last three years on tumour endoprostheses and to summarize current knowledge on this topic. The NCBI PubMed webpage was used to identify original articles published between January 2015 and April 2018 in journals with an impact factor in the top 25.9% of the respective category (orthopaedics, multidisciplinary sciences).

The following search-terms were used: tumour endoprosthesis, advances tumour endoprosthesis, tumour megaprosthesis, prosthetic reconstruction AND tumour. We identified 347 original articles, of which 53 complied with the abovementioned criteria.

Articles were categorized into (1) tumour endoprostheses in the shoulder girdle, (2) tumour endoprostheses in the proximal femur, (3) tumour endoprostheses of the knee region, (4) tumour endoprostheses in the pelvis, (5) (expandable) prostheses in children and (6) long-term results of tumour endoprostheses.

The topics of interest covered by the selected studies largely matched with the main research questions stated at a consensus meeting, with survival outcome of orthopaedic implants being the most commonly raised research question.

As many studies reported on the risk of deep infections, research in the future should also focus on potential preventive methods in endoprosthetic tumour reconstruction.

Keywords: advances tumour endoprostheses; bone metastases; bone sarcoma; endoprosthetic reconstruction; outcome; treatment

Introduction

Endoprosthetic reconstruction in orthopaedic oncology has evolved over the last 30 to 40 years, with novel endoprosthetic systems and solutions developed constantly. Endoprosthetic reconstruction has made limb-salvage surgery possible in many cases, leading to a steady decrease in the rate of amputations.1,2 Long-term results of tumour endoprostheses are important to evaluate functional outcome for patients, possible complications and implant survival.

The main objective of the present review was to identify all major studies dealing with endoprosthetic reconstruction in tumour surgery published between January 2015 and 10 June 2018. The specific focus was on long-term results and functional outcome, complications as well as recent advances and novel concepts. Within the last three years, 53 studies have been published in top-ranking journals dealing with tumour endoprostheses in orthopaedic surgery. Most studies came from China (n = 12), followed by the United States (n = 10) and the United Kingdom (n = 6). International Orthopedics was the journal with the most publications on the topic ‘advances in tumour endoprostheses’.

Materials and methods

All studies published in PubMed between January 2015 and 10 June 2018 were included in the study, after applying the specific search terms listed below. Original articles dealing with tumour endoprostheses published in English in PubMed-indexed journals with an impact factor ranking them in the top 25.9% in the categories multidisciplinary sciences or orthopaedics were considered to be eligible. This number was calculated by dividing the total number of publications in the respective categories through the rank of the journal of interest. Literature research was performed until 10 June 2018.
The following search-terms were used to identify studies on advances in tumour endoprostheses: advances tumour endoprostheses, tumour endoprosthesis, tumour megaprosthesis, prosthetic reconstruction AND tumour. Reviews, case reports, duplicates and meta-analyses were excluded manually. Altogether, 347 original studies were identified based on the four abovementioned search terms within the predefined time period. In a first step, 177 articles were excluded from further analyses with study titles not in the scope of the present review, leaving 170 articles potentially eligible. Following the review of the abstract, another 51 articles were excluded due to them not being in the scope of this review and 20 further articles due to duplication. From the remaining 100 articles, 53 had an impact factor ranking them in the top 25.9% either in the category ‘orthopaedics’ or ‘multidisciplinary sciences’ (Fig. 1). All articles with ‘case report’ in the title were excluded in the first step of article selection.

From all articles finally eligible for this study, full-text articles were either downloaded from the respective journal’s website or requested via the author’s own online library. As all necessary information could be extracted from the full-text articles, authors from specific studies were not personally contacted. The majority of the studies were retrospective in design, with only one study with a clear prospective aim.

All articles finally eligible were grouped into six categories: (1) tumour endoprostheses in the shoulder girdle, (2) tumour endoprostheses of the proximal femur, (3) tumour endoprostheses in the knee region, (4) tumour endoprostheses in the pelvis, (5) (expandable) prostheses in children and (6) long-term results of tumour endoprostheses.

Primary literature research was performed by the first author of the study (MAS), including study selection over the three steps as mentioned above. Those studies finally eligible for the study were reviewed by both the first (MAS) and senior author (AL).

As case reports were excluded from the final analysis, very novel – but to date not well established – reconstructive methods using tumour endoprostheses may not be included in this review. Furthermore, we set the journal’s rating due to the impact factor to < 25.9%, thus potentially excluding studies in small patient cohorts. We only included journals ranking in the top 25.9% of their respective category (this cut-off also includes International Orthopaedics) in order to report results of studies with a presumably high impact on readers (see Fig. 2 for the distribution of journals in the respective categories split by impact factor). No additional analyses were performed. The review protocol can be accessed by contacting the corresponding author (MAS).

**Results**

1) Tumour endoprostheses in the shoulder girdle

Seven studies were identified dealing with tumour endoprostheses around the shoulder girdle (Table 1). In a study by Maclean et al, the outcome of eight patients receiving the Bayle Walker (Stanmore® Implants Worldwide Ltd, Elstree, England, United Kingdom) reversed polarity linked
**Number of Publications Split by Impact Factor**

| Impact Factor | Expandable Prostheses | Shoulder Girdle | Proximal Femur | Knee Region | Pelvis | Long Term Results |
|---------------|------------------------|----------------|--------------|------------|--------|------------------|
| 2 - 2.99 IF   | 4                      | 8              | 6            | 8          | 4      | 2                |
| 3 - 3.99 IF   | 6                      | 8              | 4            | 6          | 4      | 2                |
| 4 - 4.99 IF   | 2                      | 8              | 6            | 8          | 4      | 2                |

*Fig. 2. Number of publications split by impact factor in the respective six categories*

**Table 1. Tumour endoprostheses in the shoulder girdle**

| Publication | Results |
|-------------|---------|
| Maclean S et al. *J Shoulder Elbow Surg* 2017*³* | – eight patients treated with the Bayley Walker (Stanmore implants Worldwide Ltd, Elstree, England, UK) reversed polarity, linked shoulder replacement  
– reason for reconstruction was chondrosarcoma in four, metastatic disease in two, Ewing sarcoma and osteomyelitis in one each  
– Trevira tube used in half of patients  
– mean follow-up of 4.1 years, survivorship of 100%  
– neuropathic pain in one patient postoperatively, no local recurrences |
| Min L et al. *Int Orthop* 2017*²* | – 15 patients with scapular hemiarthroplasty following total scapulectomy retrospectively included (2011–2014)  
– six chondrosarcomas, four osteosarcomas, two Ewing sarcomas, two myelomas, one malignant fibrous histiocytoma (MFH)  
– average follow-up of 3.4 years, with no infection, dislocation, pressure ulcer, wound healing problems or mechanical failures  
– three deaths due to lung metastases, no local recurrence  
– average range of motion (ROM): shoulder abduction 45.3°, forward flexion 65.7°  
– patients with rotator cuff reconstruction had better postoperative hand positioning, lifting ability, Musculoskeletal Tumour Society (MSTS) score and abduction functions than patients without rotator cuff reconstruction |
| Schmolders J et al. *Int Orthop* 2017*⁴* | – 30 patients treated with MUTARS (implantcast GmbH, Buxtehude, Germany) for intra-articular resection of proximal humerus, of whom 15 additionally received a Trevira tube  
– reconstruction for (semi-)malign tumours (*n* = 9) and metastases (*n* = 21)  
– mean follow-up of 2.2 years, with 96% limb survival after this time period  
– six complications in total (20%), of which three were subluxations of the prosthesis, one local recurrence, one radial palsy, one periprosthetic joint infection (*staph. epidermidis*; this patient had a Trevira tube), two periprosthetic fractures  
– mean Enneking score of 20 points  
– no difference in ROM between Trevira and non-Trevira treatment group |
| Wang B et al. *Int Orthop* 2015*⁵* | – 18 patients treated with endoprosthesis polypropylene (PPP) mesh composite after bone tumour resection of the proximal humerus included  
– pre- and postoperative pain scores (VAS) analysed, with most patients experiencing some pain alleviation two weeks after surgery  
– mean follow-up of 4.7 years, with a mean MSTS score of 66.7% at last follow-up  
– ROM was 36° for abduction and 39° for shoulder flexion  
– three complications altogether (16.7%), with one anterior subluxation  
– mean MSTS significantly better for patients in the mesh group (80.0% vs. 66.7%)  
– forward flexion, external rotation and abduction likewise significantly better in the mesh group as compared with conventional soft tissue reconstruction group |
| Fujibuchi T et al. *J Shoulder Elbow Surg* 2015*⁷* | – nine patients with proximal humeral endoprosthesis suspended by polypropylene (PPP) mesh in bone compared with 12 patients treated with PPP only attached to soft tissues  
– four of 12 patients with conventional method showed shoulder instability (33.3%), compared with none of the patients with bone-suspended method  
– shoulder flexion was better in the bone-suspended PPP-mesh method, whilst shoulder abduction was similar in both groups  
– 150 patients reviewed for infection rate treated with allograft prosthetic composites (*n* = 20), endoprostheses (*n* = 85) or osteoarticular allografts (*n* = 45) |
| Meijer ST et al. *J Shoulder Elbow Surg* 2017*⁹* | – altogether, 19 patients developed an infection (12%)  
– allografts were not associated with a higher infection rate (11% in osteoarticular allografts, 14% in endoprostheses, 10% in allograft prosthetic composites) |
| Tang X et al. *Clin Orthop Relat Res* 2015*⁸* | – 29 patients with intra-articular resections of proximal humerus reconstructed with endoprostheses and a follow-up > two years  
– synthetic mesh used in half of patients (*n* = 14), soft tissue reconstruction without mesh in the other half of patients (*n* = 15)  
– mean MSTS significantly better for patients in the mesh group (80.0% vs. 66.7%)  
– forward flexion, external rotation and abduction likewise significantly better in the mesh group as compared with conventional soft tissue reconstruction group |
shoulder endoprosthesis was analysed. In half of patients, a Trevira® tube was used to potentially enhance shoulder stability. The mean Musculoskeletal Tumour Society (MSTS) score in this patient cohort was 60.0%. This is comparable to a mean MSTS score of 66.7% reported by Schmolders et al in a study including 30 patients receiving a MUTARS® anatomical prosthesis (implantcast GmbH, Buxtehude, Germany) for intra-articular resections of the proximal humerus. In this cohort, again half of patients received a Trevira® tube. Of note, the authors discovered no difference between the Trevira® and non-Trevira® groups with regard to range of motion (ROM), being on average 38° flexion, 35° abduction and 15° external rotation. This is comparable to the 36° abduction and 39° shoulder flexion as reported by Wang et al in a cohort of 18 patients treated with endoprosthesis (LDK, Co., Ltd, Haidian, Beijing, China) polypropylene mesh composite (PROLENE® light mesh, Ethicon) after bone tumour resection of the proximal humerus. In that study, a mean MSTS score of 66.7% at last follow-up was reported. In a similar study by Tang et al, mesh-suspended proximal humeral endoprostheses (LARS Laboratoire d’Application et de Recherche Scientifique, Arc-sur-Tille, France) wrapped around the shaft of the endoprosthesis; n = 14) for malignant tumours were compared with proximal humeral endoprostheses with soft tissue reconstruction only (n = 15). Of note, a significantly better MSTS score was observed in patients with mesh reconstruction than in the soft tissue reconstruction only group (80.0% vs. 66.7%; p = 0.001). Moreover, none of the patients in the mesh group showed proximal migration of the prosthesis, compared with five of 15 patients without mesh reconstruction (33.3%; p = 0.042). This number is similar to the 33.3% of shoulder instability observed by Fujibuchi et al, although these patients had received a proximal humeral endoprosthesis wrapped in PMKM (Marlex mesh or Bard mesh, Warwick, RI, USA) fixed to soft tissues (4/12). On the other hand, the same mesh fixed to bone resulted in less shoulder instability (0/9) and better shoulder flexion (65° vs. 35° in the soft tissue suspension group; no p-value provided by authors).

In another study by Min et al, the functional outcome of patients with scapular hemiarthroplasty following total scapulectomy for tumours was investigated. The ROM, with average shoulder abduction of 45.3° and flexion of 65.7°, was relatively better than in the abovementioned studies on proximal humeral resections followed by endoprosthetic reconstruction. Moreover, rotator-cuff reconstruction was associated with a better postoperative function and improved MSTS score.

Regarding complications of proximal humeral endoprostheses in tumour surgery, Schmolders et al observed six complications in 30 patients (20.0%) treated with a MUTARS® endoprosthesis, of which one was related to deep infection (3.3%). This is less than the 12.0% infection rate reported by Meijer et al in a large study on 150 patients with proximal humeral reconstruction for tumours. In their study, osteoarticular allografts (n = 45) were not associated with a higher infection rate (11%) in comparison to endoprostheses (n = 85; 14% infection rate) or allograft prosthetic composites (n = 20; 10% infection rate).

To summarize, MSTS scores in tumour endoprostheses of the shoulder girdle range between 60.0% and 80.0%, depending on the type of reconstruction. A shoulder flexion up to 65° has been reported in one study where a synthetic mesh was fixed to the bone, thus improving shoulder stability.

### 2) Tumour endoprostheses in the proximal femur

Eight studies dealing with tumour endoprostheses of the proximal femur could be included in our review (Table 2). The largest study was performed by Henderson et al, comprising 527 patients with proximal femoral arthroplasty for primary bone tumours (benign and malignant) as well as metastases. The authors observed postoperative instability in 20 patients (4.0%), developing after a mean of 35 days. Of note, no capsular repair was not associated with a reduced rate of instability, whilst advanced age, female gender and primary bone tumours were risk factors for instability. The only protective factor against hip instability was a posterolateral approach. Moreover, the authors concluded that a posterolateral approach, together with application of a synthetic device for reconstruction of the soft tissues and a hemiarthroplasty should be best chosen to reduce instability. Corresponding to this, Du et al investigated hip instability in 58 patients with total femoral replacement for sarcoma. In 12 patients, a LARS artificial ligament was additionally wrapped spirally around the proximal end of the prosthesis, resulting in a significantly lower hip dislocation rate as compared with conventional soft tissue reconstruction. Moreover, the infection rates were comparable between LARS-augmented prostheses and conventional reconstruction (8.3% vs. 10.9%; p = 0.529). These infection rates are less than the 20.0% observed by Gorter et al in 10 patients treated with push-through total femoral endoprostheses. However, this system allows preservation of parts of the femur as well as its muscle attachments, thus potentially resulting in a better postoperative function. Interestingly, though, a mean MSTS score of 64.0% was achieved in their cohort, in comparison to 72.3% in the group by Du et al, where additional reconstruction with a LARS band significantly increased the postoperative MSTS score from 70.4% to 80.0%. Moreover, the authors observed that simple re-attachment of the gluteus maximus to the LARS band does not improve active ROM, whilst re-attachment of other external rotators (i.e.}
Table 2. Tumour endoprostheses in the proximal femur

| Publication | Results |
|-------------|---------|
| Li D et al. Int Orthop 2018 | – extra-articular resection of osteosarcoma (n = 7), chondrosarcoma (n = 7), undifferentiated pleomorphic sarcoma (UPS; n = 3) and malignant peripheral nerve sheath tumour (MPNST; n = 1) in hip/proximal femur |
| | – pelvic defect reconstructed by modular hemipelvic endoprosthesis, proximal femur reconstructed by using custom-made or modular prox. femoral endoprosthesis |
| | – one patient died perioperatively, the other 17 patients were followed-up for 35 months (mean), with 10 patients having no evidence of disease (NED), and 7 patients having died of disease (DOD) |
| | – disease-free survival (DFS) and overall-survival (OS) for all patients were 50% each |
| | – no difference in outcome between patients treated primarily at tumour centre and those with relapse (p = 0.287) |
| | – average Musculoskeletal Tumour Society (MSTS)-score of 93, with patients in whom the ilium had been resected having a lower MSTS score (p = 0.024) |
| Stevenson JD et al. Bone Joint J 2018 | – proximal femoral replacement without acetabular resurfacing reviewed in 100 patients treated between 2003 and 2013 |
| | – 74 procedures for metastases, 20 for primary bone tumours and six for myeloma |
| | – acetabular resurfacing graded according to Baker (0 = normal, 3 = protrusio acetabuli) |
| | – unilateral in 64 patients, bilateral in 36 |
| | – follow-up > one year in 49 patients (mean: 3.6 years), of whom six had Grade 1 acetabular wear and two Grade 2 acetabular wear; the others had normal acetabular wear |
| | – femoral reconstruction without acetabular resurfacing seems justified in the short term |
| Houdek MT et al. J Arthroplasty 2017 | – hemiarthroplasty in 199 patients with pathological femoral fractures between 1992 and 2014, mean follow-up of four years |
| | – conversion to total hip arthroplasty in two patients (1%) |
| | – complications in 12% of patients (n = 24), most commonly thrombosis or pulmonary artery embolism (PAE) |
| | – instability of the hip in 20 patients (4%), developing after a mean of 35 days |
| | – capsular repair not associated with reduced rate of instability |
| | – in multivariate analysis, age > 60 years, female gender, a malignant primary bone tumour and benign conditions were associated with higher rate of postoperative instability |
| | – postero-lateral approach protective against instability |
| | – no difference whether hemiarthroplasty, total hip (un)-constrained was used for reconstruction regarding development of instability |
| | – oncological resections or complications of segmental femoral prostheses can result in severe femoral bone loss |
| | – a push-through total femoral endoprosthesis (PTTF) can be used to preserve parts of the femur and its muscle attachments |
| | – 10 patients treated between 2005 and 2014 with a PTTF retrospectively included |
| | – mean follow-up of 5.3 years, with an implant, limb and prosthesis survival of 90%, 100% and 80%, respectively |
| | – four failures occurred (two infections, two mechanical failures) -- one amputation for infected prosthesis |
| | – 209 metastatic disease, 106 chondrosarcoma, 52 osteosarcoma, 38 Ewing sarcoma, 122 others |
| | – hip dislocation rate lower in patients with LARS-augmentation and active range of motion (ROM) as well as limb function better in this cohort |
| | – infection rates similar (1/12 for LARS, 5/46 for conventional total femur) |
| Hobusch GM et al. Clin Orthop Relat Res 2017 | – 16 patients with proximal femoral reconstructions for bone sarcoma and a minimum follow-up of five years |
| | – preoperatively, 14 patients were able to do sports, as compared to 11 patients at last follow-up |
| | – pre-operative University of California at Los Angeles (UCLA) and modified Weighted Activity Score levels dropped from 9 and 6 to 6 and 3 at last follow-up |
| | – 74 procedures for metastases, 106 chondrosarcoma, 52 osteosarcoma, 38 Ewing sarcoma, 122 others |
| | – infection rates similar (1/12 for LARS, 5/46 for conventional total femur) |
| | – 58 patients treated with total femoral replacement for primary bone or soft tissue sarcoma |
| | – artificial ligament (LARS; Laboratoire d’Application et de Recherche Scientifique, Arc-sur-Tille, France) was wrapped spirally around the proximal site of the total femur in 12 patients |
| | – hip dislocation rate lower in patients with LARS-augmentation and active range of motion (ROM) as well as limb function better in this cohort |
| | – infection rates similar (1/12 for LARS, 5/46 for conventional total femur) |
| Du Z et al. J Arthroplasty 2018 | – 65 patients treated with bipolar proximal femoral endoprostheses for tumours (most commonly osteosarcoma, n = 20) |
| | – mean follow-up of 9.1 years, after which degenerative changes in the acetabulum were seen in three patients (4.6%), heterotopic ossifications in 17 (26%) and prosthetic head protrusion in nine patients (13.8%) |
| | – revision became necessary in eight patients (8.3%), in whom three prostheses were converted to total hip arthroplasty |

With regard to postoperative function, Hobusch et al investigated the functional outcome of 16 patients with proximal femoral reconstructions for bone sarcomas and a minimum follow-up of five years. Prior to surgery, 14 of 16 patients (87.5%) were able to do sports. At the mean latest follow-up of 18 years (range 5–27 years), 11 of these patients had resumed sporting activities (68.8%).

Another question that arises when dealing with proximal femoral endoprostheses is the durability of hemiarthroplasty in view of chondro-osseous wear-off. With regard to this, Houdeke et al investigated the outcome of hemiarthroplasty for pathological femoral fractures in 199 patients. After a mean follow-up of four years, two patients required conversion to a total hip arthroplasty (1.0%). Reasons for conversion may be prosthetic head protrusion, as observed by Drexler et al in nine out of 65 patients (13.8%) treated with bipolar proximal femoral endoprostheses for tumours. In their cohort, three prostheses had to be converted to total hip replacement after a mean follow-up of 9.1 years (range: 2.0 to 11.8 years; 4.6%). Interestingly, according to Stevenson et al, only eight out of 49 patients treated with unipolar (n = 64) and bipolar (n = 36) endoprostheses without acetabular resurfacing showed acetabular wear after a minimum follow-up of one year, not exceeding Baker Grade 2. In tumours involving the hip joint, extra-articular resection may become necessary, as described by Li et al in a study involving 18 patients. Modular hemipelvic
prostheses and custom-made or modular proximal femoral endoprostheses were used for reconstruction.\textsuperscript{13}

Conclusively, the better the stability of a proximal femoral implant, the better the postoperative functional outcome can be expected. Moreover, bipolar reconstruction is justified in tumour patients, as acetabular wear can be expected to be minimal.

3) Tumour endoprostheses in the knee region

Nineteen articles were identified dealing with tumour endoprostheses around the distal femur and proximal tibia (Table 3). The largest study identified was that of Pala et al, including 687 distal femoral modular tumour endoprostheses implanted between 1983 and 2010.\textsuperscript{18} Of these, the majority were fixed hinge (\(n = 491\)), whilst 196 implants were rotating hinge.\textsuperscript{18} Altogether, 27.0\% of patients (\(n = 185\)) developed complications, with no difference between the rotating hinge and fixed hinge systems.\textsuperscript{18} However, all component breakages occurred in prostheses with a rotating hinge system, whilst there was no difference in rate of aseptic loosening (5.9\% vs. 2\%; \(p = 0.55\)) or infection (8.9\% vs. 6.6\%, \(p = 0.237\)) between fixed-hinge vs. rotating-hinge.\textsuperscript{18} Of note, patients with a rotating hinge system had a significantly better mean MSTS score (82.7\% compared with 76.3\%).\textsuperscript{18} This MSTS score is comparable to the 76.3\% reported by Zhang et al in a study on 41 patients (mean MSTS score 84.0\%).\textsuperscript{20} An even better MSTS score was reported by Wang et al in a study on 41 patients reconstructed with allograft-prosthesis composites and rotating-hinge knee prostheses for tumours, being 93.4\% on average.\textsuperscript{21}

The overall failure rate of the GMRS prosthesis as evaluated by Pala et al was 29.1\% (72/247), with infections being most common (\(n = 23\)), followed by soft tissue failure (\(n = 21\)).\textsuperscript{20} These rates are comparable with those reported by Bus et al in a study on 101 patients with 110 reconstructions with a MUTARS\textsuperscript{®} implant of the distal femur or proximal tibia for malignancy.\textsuperscript{22} Of 63 complications observed (57.3\%), 14 were due to infection and 15 due to structural failure.\textsuperscript{22} Also in the cohort of Holm et al, most complications observed in this study on 50 patients with megaprostheses of the knee joint and total femur were due to deep infection (\(n = 19\)).\textsuperscript{23} Additionally, in the cohort by Hardes et al, the most common complication in 98 patients treated with a MUTARS\textsuperscript{®} endoprosthesis of the proximal tibia was due to infection (\(n = 15\)).\textsuperscript{24} Moreover, eight of these patients ultimately required an amputation.\textsuperscript{24}

Twenty-seven stem fractures (12.2\%) were reported by Hauer et al in a study involving 221 patients treated with the Kotz Modular Femoral Tibial Reconstruction System (KMFTR\textsuperscript{®}; Stryker Inc., Rutherford, NJ, USA).\textsuperscript{25} Notably, stem fractures were associated with a significantly smaller stem diameter and a significantly longer extramedullary component.\textsuperscript{25} Therefore, augmented systems with osteoarticular allografts may be used, as described by Qu et al in a study on 29 patients treated with cortical strut bone grafts combined with long-stem endoprosthetic reconstruction in the knee joint.\textsuperscript{26} In their study, bone healing was observed in 23 of 29 patients reconstructed with cortical strut allografts in addition to tumour endoprostheses after a mean of 3.9 years.\textsuperscript{26}

In patients receiving endoprostheses or osteoarticular allografts in the proximal tibia, mean MSTS scores of 88.6\% and 91.7\% were observed by Albergo et al.\textsuperscript{27} Interestingly, failure rates were higher in the osteoarticular allograft group as compared with the group of patients reconstructed with endoprostheses (18.0\% vs. 27.0\% at five years). Moreover, mechanical failure was the most common reason for revision in patients with endoprostheses, whilst infections were the main cause in the osteoarticular allograft group.\textsuperscript{27}

Regarding periprosthetic joint infections, the use of silver-coated implants in order to minimize infection risk is of interest. In the study by Hardes et al, the infection rate was lower in 56 silver-coated implants of the proximal tibia in comparison to 42 titanium-based implants in the same body region after a median follow-up of 8.2 years (8.9\% vs. 16.7\%).\textsuperscript{28} Additionally, only one patient in the silver-coated implant group had to undergo an amputation, as compared with three patients in the titanium-based group.\textsuperscript{28}

With regard to osseointegration of tumour endoprostheses, Liang et al compared the functional and oncological outcomes of 62 cases with uncemented tibial fixation and 58 cases with cemented tibial fixation in distal femoral replacement for bone tumours.\textsuperscript{29} Osseointegration was observed in 64.3\% of patients with an uncemented
Table 3. Tumour endoprostheses of the knee region

| Publication | Results |
|-------------|---------|
| Hardes J et al. Int Orthop 2018 | – 98 patients undergoing reconstruction with MUTARS (implantcast GmbH, Buxtehude, Germany) endoprostheses following intra-articular resection of proximal tibia – median age 18 years, median follow-up 98 months – five- and ten-year implant survival rates of 90.5% and 74.5% – cumulative incidence of implant failure 29% at five years, with infections being most frequent reason for secondary amputation |
| Pesenti S et al. Int Orthop 2018 | – 15 patients (mean age of 25.2 years) included – nine patients underwent surgery with allograft and sparing of epiphysis – six patients received a megaprosthesis – decreased knee flexion in loading response phase in both groups upon gait analysis – no difference in gait pattern between treatment groups, using Gait Deviation Index and Gilette Gait Index – 98 patients treated with MUTARS endoprostheses (silver-coated n = 56; titanium n = 42) retrospectively analysed for infections – infection rate lower in silver than titanium group (8.9% vs. 16.7%), as was implant survival (90% vs. 84%) - secondary amputation necessary in 14.3% of silver-coated implants, compared with 37.5% of titanium implants |
| Hardes J et al. J Arthroplasty 2017 | – mean age 33.9 years, mean follow-up of 4.5 years – no difference in anterior knee pain or Musculoskeletal Tumour Society (MSTS) score between both groups – complication rates comparable between the two groups – resurfacing group significantly more often showed peripatellar calcifications |
| Etchebehere M et al. J Bone Joint Surg Am 2016 | – 48 patients with and 60 without patellar resurfacing following resection of femoral tumour with endoprosthetic reconstruction – mean age 33.9 years, mean follow-up of 4.5 years – no difference in anterior knee pain or Musculoskeletal Tumour Society (MSTS) score between both groups – complication rates comparable between the two groups – resurfacing group significantly more often showed peripatellar calcifications |
| Zhou CE et al. Clin Orthop Relat Res 2016 | – 27 patients (mean age 30 years) undergoing revision surgery for failed distal femoral prosthesis using the Compress Compliant Pre-stress (CPS, Zimmer Biomet, Warsaw, IN, USA) implant – cumulative incidence for mechanical failure was 11%, occurring after a median of five months – incidence of remaining failures was 18%, most commonly due to deep infections – median MSTS score of 27 (after a minimum of two years of follow up or until implant removal) |
| Holm CE et al. Int Orthop 2018 | – megaprosthesis of distal femur (n = 29), proximal femur (n = 9), proximal tibia (n = 9) and total femur (n = 3) – three years from primary surgery to first revision, in 27 patients altogether (54%)– deep infection as main cause for revision (n = 19). 78 revision surgeries in total – implant revision-free survival at five and ten years: 43% and 24% – finally amputation in six patients (12%) – overall survival at five and ten years: 89% and 83% (with 30 osteosarcomas, nine chondrosarcomas, 6 giant cell tumours, four Ewing sarcomas and one angiosarcoma of bone) – 22 of 50 patients died during follow-up (44%; causes not explored) |
| Hauer TM et al. J Arthroplasty 2018 | – 221 patients treated with the Kotz Modular Femoral Tibial Reconstruction System (KMFTR, Stryker Inc. Rutherford, NJ, USA) reviewed for implant fracture (112 distal femur, 53 proximal tibia, 40 proximal femur, 13 total femur, three distal femur + proximal tibia) – system failure in 27 patients (12%), most commonly in the distal femur (n = 21) – mean time to fracture of system: seven years – in patients with stem fracture, the stem diameter was significantly smaller (12 vs. 14 mm, p = 0.001), and with a significantly longer extramedullary component (18 vs 15 cm, p = 0.04) |
| Goulding KA et al. Clin Orthop Relat Res 2017 | – two for proximal humerus, two for humeral diaphysis, seven for distal humerus, two for proximal ulna – minimum follow-up of two years in 12 implants, of which six required revision – the compressive osseointegration endoprosthesis allows reconstruction of difficult revisions or sarcoma resections in the upper extremity – however, complications frequently occur |
| Albergo JI et al. Clin Orthop Relat Res 2017 | – 133 patients treated between 1990 and 2012 at two tumour centres with proximal tibial resections for primary bone tumours were included – reconstruction either with osteoarticular allograft (n = 45) or endoprostheses (n = 88) – mean follow-up of 9.5 years for endoprostheses and 7.4 years for osteoarticular allografts – implant failure for endoprosthetic reconstruction was 18% at five years, compared with 27% for osteoarticular allografts – 51 endoprostheses failed (58%, most commonly mechanical failure), in comparison to 19 osteoarticular allografts (42%, most frequently infection) |
| Bus MP et al. Clin Orthop Relat Res 2017 | – inclusion of 101 patients with a total of 110 reconstructions (after exclusion of four cases lost to follow-up) – median follow-up of 8.9 years – most common diagnosis osteosarcoma (n = 56) – altogether, 63 complications were observed – Hydroxylapatite (HA) coated uncemented implants with lower risk for loosening – infections occurred in 14 reconstructions and structural complications in 15 reconstructions – at last follow-up, 90 patients (89%) had a MUTARS in situ (although some had been salvaged after complication) |
| Etchebehere M et al. J Arthroplasty 2016 | – distal femoral replacement in 108 patients with malignant (n = 81), benign (n = 11), metastatic (n = 15) and non-tumoral (n = 1) lesions – patellar height was calculated with Insall-Salvati ratio (ISR) and Insall-Salvati patellar tendon insertion ratio (PTR) directly postoperatively and at last follow-up – average follow-up of 4.5 years – patellar height was not associated with range of motion (ROM), anterior knee pain or extension lag, but generally decreased significantly after distal femoral resection (from 1.45 to 1.44 for the PTR) |
| Barut N et al. Int Orthop 2015 | – 17 patients with 18 periprosthetic fractures following implantation of a tumour endoprosthesis in hip or knee were included – 12 fractures occurred after femoral resection (67%) and six following tibial resection – most common fracture type was located in the femoral or tubial shaft – most patients underwent surgery for periprosthetic fracture (n = 16), with only one patient receiving another implant – overall probability of failure following periprosthetic fracture for any reason was 27% at five and 35% at ten years |
| Qu H et al. Bone Joint J 2015 | – 29 patients included, treated with cortical strut bone graft combined with long-stem endoprosthetic reconstruction (cemented) – bone healing in 23 patients (86%) after a mean of 3.9 years – mean MSTS score was 85% (57 to 97) and five-year implant survival 81% – ten complications observed (four non-unions, two aseptic loosenings, two infections, one haematoxina, one patellar dislocation) |

(continued)
system. Moreover, the surgical time was reduced by 26 minutes on average when implanting an uncemented system, prompting the conclusion that in tumour patients with a poor general condition uncemented systems are likewise suitable with the advantage of shortened surgery time.\textsuperscript{29} There was no difference in revision rates between cemented and uncemented systems (9.6% vs. 5.4%, p = 0.399).

Another interesting finding regarding the postoperative function of tumour endoprostheses around the knee joint was reported by Etchebehere et al in a study involving 108 patients with distal femoral endoprosthetic replacement for tumoural (n = 107) and non-tumoural reasons (n = 1).\textsuperscript{30} They investigated the relative patellar height by applying the Insall-Salvati ratio (ISR) as well as the Insall-Salvati patellar tendon insertion ratio (PTR) directly postoperatively and at last follow-up.\textsuperscript{30} Of note, the patellar height was not associated with ROM, anterior knee pain or extension lag, but generally decreased significantly after the operation (from 1.45 to 1.4 for the PTR (ratio of two lines drawn on lateral radiographic images of the knee)).\textsuperscript{30}

Regarding patellar resurfacing, Etchebehere et al analysed the outcomes of 48 patients receiving tumour endoprostheses of the distal femur or proximal tibia with patellar resurfacing and 60 patients without patellar resurfacing.\textsuperscript{31} There was no difference in anterior knee pain between the groups.\textsuperscript{31} Moreover, anterior knee pain did not significantly alter extensor lag, range of motion, reoperation or complication rates.\textsuperscript{31} Although complications in general were similar between the resurfaced and non-resurfaced groups, peripatellar calcifications were more frequently seen in the resurfaced group.\textsuperscript{31} Nevertheless, mean MSTS scores of 81% and 71% were observed for the non-patellar resurfacing and patellar resurfacing groups respectively, which was not statistically significant (p = 0.30).\textsuperscript{31} Consequently, the decision in favour of or against patellar resurfacing should be made individually in each case.

Another interesting study investigated the postoperative mobility in patients receiving allografts (n = 15) or megaprostheses (n = 6) for malignant tumours of the knee region.\textsuperscript{32} An allograft augmented with a fibula graft was implanted in cases where more than 2 cm above the knee joint could be
kept. According to Pesenti et al, there was no difference in gait pattern between the groups, albeit in the megaprosthesis group, a decreased knee flexion during the load and stance phase was observed.\(^{32}\) Moreover, the Gait Deviation Index (GDI), was significantly lower in both groups as compared to a control group.\(^{32}\) Therefore, sparing of the epiphysis may not significantly increase the functional outcome in patients with tumours around the knee joint.

With regard to functional outcomes, Lang et al investigated the postoperative ability of patients to perform sports following reconstruction with modular tumour endoprostheses around the knee joint.\(^{33}\) Prior to implantation, 24 of 27 (89.0%) patients were able to do sports, as were 24 patients at last follow-up (89.0%). Importantly, the rate of sporting activity increased steadily over the years, from 33.0% over 74.0% to the abovementioned 89.0% at an average follow-up of 11 years.\(^{33}\) Even revision surgeries that became necessary in 14 patients had no influence on the patients’ activity levels.\(^{33}\)

One study elaborating the outcome of tumour patients with periprosthetic fractures was performed by Barut et al.\(^{34}\) They investigated 17 patients with 18 periprosthetic fractures following endoprosthetic replacement for tumours around the knee joint.\(^{34}\) Sixteen of these patients underwent surgery, with only one requiring another implant. Overall probability of failure following periprosthetic fracture for any reason was 55.0% at 10 years.\(^{34}\)

Another problem in reconstruction with (tumour) megaprostheses is the huge bone loss in case of failed treatment, limiting further reconstructions. With regard to this, Zimel et al have discovered low rates of mechanical failure in 27 patients treated with the Compress\(^{8}\) Compliant Prestress Device (Zimmer Biomet, Warsaw, IN, USA) for failed reconstruction of the distal femur for tumoural (\(n=26\)) and non-tumoural (\(n=1\)) indications.\(^{35}\) The cumulative incidence of mechanical failure was 11% at five years and did not increase thereafter. A median MSTS score of 90.0% was reported, which is surprisingly high.\(^{35}\) Noteworthy, the Compress\(^{8}\) Compliant Prestress Device requires few bone contacts in the shaft, but has a shallow learning curve.

Contrary to this, Goulding et al have investigated the outcome of a compressive osseointegration endoprosthesis (Compress\(^{8}\) Compliant Prestress Device; Zimmer Biomet, Warsaw, IN, USA) coupled with modular prostheses in nine patients with a total of 13 endoprosthetic replacements and discovered a high complication rate.\(^{36}\) The revision rate of 50% in 12 implants with a follow-up > 24 months was relatively high.\(^{36}\)

### 4) Tumour endoprostheses in the pelvis

Four studies were focused on tumour endoprostheses and prosthetic reconstruction in the pelvis (Table 4). Two of these described the results of 3D-printed pelvic endoprostheses for large bone defects following wide tumour resection, whilst the third investigated the outcome with the Integra\(^{8}\) ice-cream cone prosthesis (Lépine, Genay, France) and the fourth study reported the results on a custom-designed hemipelvic prosthesis.

In the Integra\(^{8}\) ice-cream cone study by Issa et al, 24 patients with periacetabular malignant tumours – necessitating Type II ± Type III resections – were followed-up for a mean of 4.1 years.\(^{37}\) Mean MSTS score was 72.0% at last follow-up.\(^{37}\) However, complications were observed in 14

---

**Table 4. Tumour endoprostheses in the pelvis**

| Study | Details |
|-------|---------|
| Liang H et al. Bone Joint J 2017\(^{38}\) | 35 patients treated with 3D-printed pelvic endoprostheses between 2013 and 2015 (three iliac prostheses, 12 standard hemipelvic prostheses, 20 screw-rod connected hemipelvic prostheses) - lesions were Type I in three, Type II in five, Type III in two, Type IV in one and Type I–IV in three - implants used for osteosarcoma (n = 11), chondrosarcoma (n = 9), Ewing sarcoma (n = 6) and others (n = 9) - wide margins in 15 patients (42.9%), marginal in 14 (40%) and intralesional in six (17.1%) - after a mean follow-up of 1.7 years, 25 patients had no evidence of disease (NED), 5 were alive with disease (AWD) and five patients were dead of disease (DOD) - mean MSTS-score of 63.7%, and generally lower for patients with screw-rod connected prosthetic reconstruction - complications developed in nine patients (seven with delayed wound healing requiring debridement, two with hip dislocation) |
| Wang B et al. Int Orthop 2015\(^{39}\) | Six patients included treated for a malignant pelvic tumour involving regions II/IV with a hemipelvic prosthesis (LDK, Co. Ltd., Haidian, Beijing, China) - mean postoperative MSTS score was 53.9% - stress tests were performed at a force of 400 N when sitting and standing on two feet - in normal pelvis, stress distribution was around acetabulum, arcuate line, SI joint and sacral midline in both positions - in the reconstructed pelvis, stress distribution was mainly concentrated on the connecting rods of the acetabular component and the proximal segment of the pedicle rods - generally higher peak stresses in reconstructed pelvis as compared to normal pelvis |
| Issa SP et al. Int Orthop 2018\(^{40}\) | – Integra\(^{8}\) (Lépine, Genay, France) ice-cream-cone prosthesis used in 24 patients with periacetabular malignant tumours (Type II or Type II–III resections) - after a mean follow-up of 4.1 years, patient survival was 88% (of whom 15 had NED) - mean MSTS score was 72% at last follow-up - in 14 patients, at least one complication developed, with four infections, four dislocations and two mechanical failures - five-year implant survival was 75% |
| Wang B et al. Int Orthop 2018\(^{41}\) | 11 patients with periacetabular malignant bone tumours treated by personalized 3D-printed hemipelvic prosthesis - average follow-up of 1.3 years - hip dislocation observed in two patients and delayed wound healing in one - pre- vs. postoperative visual analogue scale (VAS) score was 4.5 vs. 1.8 - mean Musculoskeletal Tumour Society (MSTS) score at last follow-up was 64% |

---

\[\text{ADvANCES IN TUMOUR ENDOprostheses: A SySTEMatic REvIEW}\]
patients (58.3%), with infections being most common (n = 4). In comparison to periacetabular resections, the mean MSTS scores for hemipelvic resections were relatively lower in the other studies, ranging from 53.9% to 64.0%. The largest of the three studies by Liang et al investigating the outcome after hemipelvic resection involved 35 patients reconstructed with 3D-printed pelvic endoprostheses. Nine patients (25.7%) developed complications (seven wound healing deficits, two hip dislocations), albeit no deep infection was observed, after a median of 20.5 months. In another study by Wang et al, the outcomes of 11 patients receiving personalized 3D-printed hemipelvic endoprostheses were investigated. Comparable to the study by Liang et al, one patient presented with delayed wound healing and two patients had hip dislocation. The mean MSTS score at last follow-up was 64.0%, which is comparable with the 53.9% observed by Wang et al in six patients receiving hemipelvic prostheses for bone tumours. The authors did not only investigate the subjective outcome, but also performed stress tests with patients sitting or standing on two feet. Whilst stress distribution in the normal pelvis was mainly located around the acetabulum, arcuate line, sacroiliac joint and sacral midline both when sitting or standing, the stress distribution moved to the connecting rods of the acetabular component and the proximal segment of the pedicle rods in patients with reconstructions. This highlights that peak stresses are generally higher in the reconstructed pelvis, which should be considered in the development of new implants.

5) (Expandable) prostheses in children

Seven original articles were identified dealing with expandable tumour endoprostheses in young patients (Table 5). Gilg et al investigated 51 custom-made growing prostheses (Juvenile Tumour System, Stanmore® Implants Worldwide Ltd, Elstree, England, UK) used for reconstruction of primary bone sarcoma of the femur and proximal tibia in 50 children between 2003 and 2014. Three- and five-year revision-free survival were 81.7% and 61.6%, with deep infections (Henderson Type IV) being most common (n = 10). In another study by Arteau et al, distal femoral growing prostheses in 23 children were investigated (Repiphysis® (Wright Medical Technology Inc., Arlington, TN, USA)) in 14 patients, custom Biomet® prosthesis (Zimmer Biomet, Warsaw, IN, USA) in eight, Juvenile Tumour System (Stanmore® Implants Worldwide Ltd, Elstree, England, UK) in one patient), with specific focus on leg-length discrepancy. In 65% of patients, the proximal tibial epiphysis – although intact except for the insertion point of the tibial stem – grew less over time than the contralateral epiphysis. Interestingly, in one patient an overgrowth of the proximal physis was observed. Corresponding to this, Cipriano et al reported the outcomes of the Repiphysis® (Wright Medical Technology Inc., Arlington, TN, USA) expandable prosthesis in 10 young patients with osteosarcoma. Altogether, they observed 37 implant-related complications (amounting to an average of 3.7 complications per patient), requiring 15 revision surgeries. Slightly fewer complications were reported by Schinhan et al on the identical system, with a mean of 2.6 complications per patient. Each patient in this cohort underwent a mean of 4.4 lengthening procedures (invasive, minimally invasive and non-invasive) with an average limb elongation of 70.8 mm. This is more than the 42.7 mm reported by Gilg et al and the 39 mm observed in the study by Staals et al.

Interestingly, mean MSTS scores of 88.3% and 87.8% were observed in the study by Gilg et al and Schinhan et al compared to 64.0% and 67% reported by Staals et al and Cipriano et al. In the latter three studies, the Repiphysis® system was used, where no clear tendency towards a poorer outcome can be observed.

Additionally, Torner et al reported on a mean lengthening of 36.4 mm in seven patients receiving a MUTARS® Xpand Growing Prosthesis (implantcast GmbH, Buxtehude, Germany) in the distal femur (n = 6) and proximal femur (n = 1), and a mean MSTS score of 87.7%. Notably, none of the patients in this cohort developed any local recurrence and one deep infection was treated by arthroscopy and antibiotics. On the other hand, seven out of 50 patients (14.0%) in the cohort by Gilg et al finally underwent amputation due to infection (n = 4) or local recurrence (n = 3). A lower rate was observed by both Arteau et al, with two out of 23 patients undergoing amputation for local recurrence (8.7%), and Schinhan et al, with 2 out of 71 patients (2.8%) undergoing amputation, again due to local recurrences.

Another technique that may be used in reconstruction of large bone defects, especially in children, are resurfaced allograft-prosthetic composites, as described in the study by Campanacci et al including 19 young patients treated with this method for bone tumours of the proximal tibia. The mean implant survival was 68 months, with major complications including six allograft fractures, two non-union and one infection. The most common complication was leg-length discrepancy that could be lowered to a mean of 1.9 cm at latest follow-up following contralateral epiphysiodosis. The mean MSTS score was 73.3% in this cohort.

6) Long-term results of tumour endoprostheses

Altogether, six articles published between 2015 and 2018 meeting the abovementioned criteria were dealing with the long-term outcome of tumour endoprostheses in primary and metastatic bone disease as well as soft tissue sarcomas (Table 6). Regarding very long-term complications, Grimer et al observed in their cohort of 230 patients treated
with growing \((n = 46)\) and non-growing \((n = 184)\) tumour endoprostheses in the knee joint, hip, humerus and pelvis. 2.7 further operations on average (equivalent to 610 additional surgeries), most commonly aseptic loosening \((n = 112)\), re-bushing \((n = 40)\) and deep infection \((n = 25)\) after a mean follow-up of 29.4 years.\(^{48}\) On the other hand, Capanna et al observed in their cohort of 200 patients treated with the Megasystem C (Waldemar LINK® GmbH & Co. KG, Hamburg, Germany) for tumours of the hip and knee 71 failures in 58 implants, most commonly due to mechanical reasons \((59.2\% \text{ of all failures, including aseptic loosening, soft tissue failure and structural failure})^{49}\).

In order to minimize the risk of implant fractures, extra-cortical plates may be used for augmentation of short-stemmed endoprostheses, as described in the study by Stevenson et al.\(^{50}\) In their cohort of 37 patients reconstructed with tumour endoprostheses augmented by extra-cortical plates for large resections exceeding > 70.0% of the bone’s original length, there was no difference in implant survival when compared to standard stemmed controls at any site (humerus, hip and knee).\(^{50}\)

Another important topic regarding long-term outcome of tumour endoprostheses is the postoperative mobility of patients. In the study by Bernthal et al, the postoperative...
mobility of 24 patients treated with tumour endoprostheses in the hip ($n=7$) and knee ($n=17$) was analysed using gait analysis and O2-consumption.\textsuperscript{51} According to their results, the median O2-consumption was not significantly different in the tumour prostheses group as compared with healthy controls.\textsuperscript{51} Interestingly, patients with proximal tibial replacements had reduced knee extension (reduced by 84%) and flexion strength (reduced by 35%) in comparison to patients in the other reconstruction groups, which is comparable to the results of the study by Benevenia et al.\textsuperscript{32}

Very few studies were discovered in the present review dealing with smaller joints such as the ankle and the wrist. In the study by Wang et al, the outcome of 10 patients treated with unipolar prostheses after resection of Grade III giant cell tumours in the distal radius was investigated.\textsuperscript{52} In their cohort, six out of 10 patients developed a complication, including two wrist subluxations and one aseptic loosening.\textsuperscript{52} In two patients pain associated with the implant was still present at last follow-up.

The outcome of intracalary implants in the femur ($n=21$), humerus ($n=18$) and tibia ($n=5$) was reported by Benevenia et al.\textsuperscript{51} In total, 13 complications were observed in 44 patients, most commonly due to structural failure ($n=6$).\textsuperscript{53} Of note, the majority of complications were observed in implants of the femur.\textsuperscript{53} A mean MSTS score of 77.0% was observed for all locations, with cemented implants having a better score.\textsuperscript{53}

In summary, long-term outcomes following endoprosthetic reconstruction in tumour surgery are relatively good in terms of functionality. However, complications occur frequently and do not only pose a threat to the treating team but also significantly affect a single patient’s perspective on postoperative outcome.

### Discussion

In the studies compiled in the present review, the authors focused on functional outcomes, complications and long-term follow-up of tumour endoprostheses used in orthopaedic oncology. Regarding functional outcomes – usually evaluated with the MSTS score – these did not significantly differ between studies dealing with identical body regions. However, there was a tendency towards poorer functional outcomes the more aggressive the resections had been and the larger the used implants

| Publication | Results |
|-------------|---------|
| Bernthal NM et al. \cite{1} | 69 patients undergoing endoprosthetic reconstruction for bone sarcoma of lower extremity |
| Stevenson JD et al. \cite{2} | 37 patients with limb salvage for primary bone neoplasm between 1998 and 2013 (nine proximal humerus, nine proximal femur, 13 distal femur, six proximal tibia) |
| Grimer RJ et al. \cite{3} | 230 patients with a mean follow-up of 29.4 years were included, treated with endoprosthetic replacement for malignant bone tumours |
| Benevenia J et al. \cite{4} | 41 patients treated with 44 intracalary implants between 2008 and 2013 (21 femur, 18 humerus, five tibia) |
| Wang B et al. \cite{5} | ten patients treated with unipolar prosthesis after resection of Grade III giant cell tumours in the distal radius |
| Capanna R et al. \cite{6} | 200 patients with minimum follow-up of two years included, treated with Megasytem C megaprostesis for tumours of hip or knee |

*Table 6. Long-term results of tumour endoprostheses*
were. Moreover, the larger the implants, the more frequently complications were observed. Specifically, infections posed a major problem in endoprosthetic reconstruction with megaprostheses. Of note, only a few studies were identified dealing with preventive procedures to lower the risk of infection in tumour surgery, e.g. the use of silver-coated implants. In this field, further in-depth research should be performed in order to lower the risk of infection, which often leads to revision and implant explantation with major consequences for the patient. Another important issue in endoprosthetic reconstruction with large tumour endoprostheses is the fact that patients are getting older despite staying more active, wherefore the risk for periprosthetic fractures is raised. Of note, only one study was identified in the present review dealing exclusively with periprosthetic fractures around tumour endoprostheses.34

There are some limitations in the present review. As we excluded studies journals with an impact factor ranking > 25.9% in the respective category, results on smaller patient cohorts or from small-volume centres may not have been discussed. Moreover, as we excluded all case reports, very novel advances in endoprosthetic reconstruction of tumour endoprostheses may not have been considered.

Conclusion

The long-term results of tumour endoprostheses used in orthopaedic oncology depend on several factors, including the postoperative functionality, patient satisfaction and the rate of complications.

Over the last three years, 53 studies have been published dealing with tumour endoprostheses. However, significant novelties were lacking amongst these studies. On the other hand, many studies focused on long-term results on already established reconstructive procedures, which is equally important with regard to clinical applicability of specific reconstructive techniques.

In the next few years, studies should also focus on prevention of frequently observed complications – especially deep infections of tumour endoprostheses and periprosthetic fractures, as these issues pose a major threat to orthopaedic surgeons and treated patients.

FUNDING STATEMENT

Although none of the authors has received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article, benefits have been or will be received but will be directed solely to a research fund, foundation, educational institution, or other non-profit organization with which one or more of the authors are associated.

ICMJE CONFLICT OF INTEREST STATEMENT

DA reports honorarium and travel expenses for a lecture, unrelated to this study from Lilly and travel expenses for a meeting unrelated to this study from Implantcast GmbH.

AL reports grants/grants pending paid to his institution outside the submitted work from Metronic, Johnson & Johnson, Alphamed. All other authors declare no conflict of interest.

REFERENCES

1. Williard WC, Collin C, Casper ES, Hajdu SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992;175:389–396.

2. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269–275.

3. Maclean S, Malik SS, Evans S, Gregory J, Jeys L. Reverse shoulder endoprosthetic reconstruction for pathologic lesions of the proximal humerus: a minimum 3-year follow-up. J Shoulder Elbow Surg 2017;26:1990–1994.

4. Schmolders J, Koob S, Scheipers P, et al. Silver-coated endoprosthetic replacement of the proximal humerus in case of tumour: is there an increased risk of periprosthetic infection by using a trevira tube? Int Orthop 2017;41:423–428.

5. Wang B, Wu Q, Liu J, Yang S, Shao Z. Endoprosthetic reconstruction of the proximal humerus after tumour resection with polypropylene mesh. Int Orthop 2015;39:501–506.

6. Tang X, Guo W, Yang R, Tang S, Ji T. Synthetic mesh improves shoulder function after intraarticular resection and prosthetic replacement of proximal humerus. Clin Orthop Relat Res 2015;473:1464–1471.

7. Fujibuchi T, Matsumoto S, Shimoji T, et al. New endoprostheses suspension method with polypropylene monofilament knitted mesh after resection of bone tumors in proximal humerus. J Shoulder Elbow Surg 2015;24:882–888.

8. Min L, Zhou Y, Tang F, et al. Reconstruction with scapular hemiarthroplasty endoprostheses after scapuloectomy for malignant tumour. Int Orthop 2017;41:1057–1063.

9. Meijer ST, Paulino Pereira NR, Nota SPFT, Ferrone ML, Schwab JH, Lozano Calderón SA. Factors associated with infection after reconstructive shoulder surgery for proximal humerus tumors. J Shoulder Elbow Surg 2017;26:931–938.

10. Henderson ER, Keeney BJ, Pala E, et al. The stability of the hip after the use of a proximal femoral endoprostheses for oncological indications: analysis of variables relating to the patient and the surgical technique. Bone Joint J 2017;99-B:533–537.

AUTHOR INFORMATION

1Department of Orthopaedics and Trauma, Medical University of Graz, Austria.
2Department of General Orthopaedics and Tumour Orthopaedics, University Hospital Muenster, Germany.
3Tumour Orthopaedics, HELIOS Klinikum Berlin-Buch, Germany.

Correspondence should be sent to: Maria A. Smolle, Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036 Graz, Austria. Email: maria.smolle@medunigraz.at

© 2019 The author(s)

All other authors declare no conflict of interest.

This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.
11. Du Z, Tang S, Yang R, Tang X, Ji T, Guo W. Use of an artificial ligament decreases hip dislocation and improves limb function after total femoral prosthetic replacement following femoral tumor resection. J Arthroplasty 2018;33:1507–1514.

12. Gorter J, Ploegmakers JJW, Ten Have BLEF, Schreuder HBW, Jutte PC. The push-through total femoral prosthesis offers a functional alternative to total femoral replacement: a case series. Int Orthop 2017;41:2233–2244.

13. Li D, Xie L, Guo W, Tang X, Ji T, Yang R. Extra-articular resection is a limb-salvage option for sarcoma involving the hip joint. Int Orthop 2018;42:695–703.

14. Hobusch GM, Bollmann J, Puchner SE, et al. What sport activity levels are achieved in patients after resection and endoprosthetic reconstruction for a proximal femur bone sarcoma? Clin Orthop Relat Res 2017;475:817–826.

15. Houdek MT, Wyles CC, Labott JR, Rose PS, Taunton MJ, Sim FH. Durability of hemiarthroplasty for pathologic proximal femur fractures. J Arthroplasty 2017;32:3607–3610.

16. Drexler M, Gortzak Y, Sternheim A, Kollender Y, Amar E, Bickels J. The radiological evaluation of the hip joint after prosthetic arthroplasty of the proximal femur in patients with a tumour using a bipolar femoral head. Bone Joint J 2015;97-B:1704–1709.

17. Stevenson JD, Kumar VS, Cribb GL, Cool P. Hemiarthroplasty proximal femoral endoprostheses following tumour reconstruction: is acetabular replacement necessary? Bone Joint J 2018;100-B:101–108.

18. Pala E, Trovarelli G, Angelini A, Ruggieri P. Distal femur reconstruction with modular tumour prostheses: a single institution analysis of implant survival comparing fixed versus rotating hinge knee prostheses. Int Orthop 2016;40:2171–2180.

19. Zhan C, Hu J, Zhu K, Cai T, Ma X. Survival, complications and functional outcomes of cemented megaprosthesis for high-grade osteosarcoma around the knee. Int Orthop 2018;42:927–938.

20. Pala E, Trovarelli G, Calabrotà T, Angelini A, Abati CN, Ruggieri P. Survival of modern knee tumor megaprosthesis: failures, functional results, and a comparative statistical analysis. Clin Orthop Relat Res 2015;473:891–899.

21. Wang CS, Wu PK, Chen CF, Chen WM, Liu CL, Chen TH. Bone-prosthesis composite with rotating hinged-knee prosthesis in limb salvage surgery for high-grade sarcoma around the knee. J Arthroplasty 2015;30:90–94.

22. Bus MP, van de Sande MA, Fiocco M, Schaap GR, Bramer JA, Dijkstra PD. What are the long-term results of MUELET® modular endoprostheses for reconstruction of tumor resection of the femoral diaphysis and proximal tibia? Clin Orthop Relat Res 2017;475:708–718.

23. Holm CE, Bardram C, Riecke AF, Horstmann P, Petersen MM. Implant and limb survival after resection of primary bone tumors of the lower extremities and reconstruction with mega-prostheses: fifty patients followed for a mean of fourteen years. Int Orthop 2018;42:1175–1181.

24. Hardest J, Henrichs MP, Gosheger G, et al. Tumour endoprosthesis replacement in the proximal tibia after intra-articular knee resection in patients with sarcoma and recurrent giant cell tumour. Int Orthop 2018;42:2475–2481.

25. Hauer TM, Houdek MT, Bhumbra R, Griffin AM, Wunder JS, Ferguson PC. Component fracture in the Kotz modular femoral tibial reconstruction system: an under-reported complication. J Arthroplasty 2018;33:544–547.

26. Qu H, Guo W, Yang R, et al. Cortical strut bone grafting and long-term endoprosthetic reconstruction following massive bone tumour resection in the lower limb. Bone Joint J 2015;97-B:544–549.

27. Albergo JI, Gaston CL, Aponte-Tinao LA, et al. Proximal tibia reconstruction after bone tumor resection: are survivorship and outcomes of endoprosthetic replacement and ostearticular allograft similar? Clin Orthop Relat Res 2017;475:676–682.

28. Hardes J, Henrichs MP, Hausschild G, Nottrott M, Guder W, Streitburger A. Silver-coated megaprosthesis of the proximal tibia in patients with sarcoma. J Arthroplasty 2017;32:2208–2213.

29. Liang H, Guo W, Yang R, Tang X, Yan T. Comparison between un cemented and cemented fixation for the tibial component in distal femoral replacement: a clinical and radiological study. Int Orthop 2018;42:2249–2261.

30. Etchebehere M, Lin PP, Moon BS, Yu J, Li L, Lewis VO. Patellar height decreasing after distal femur endoprosthesis reconstruction does not affect functional outcome. J Arthroplasty 2016;31:442–445.

31. Etchebehere M, Lin PP, Bird JE, et al. Patellar resurfacing: does it affect outcomes of distal femoral replacement after distal femoral resection? J Bone Joint Surg Am 2016;98:544–551.

32. Pesenti S, Peltier E, Pomero V, et al. Knee function after limb salvage surgery for malignant bone tumor: comparison of megaprosthesis and distal femur allograft with epiphysis sparing. Int Orthop 2018;42:427–430.

33. Lang NW, Hobusch GM, Funovics PT, Windhager R, Hofstaetter JG. What sports activity levels are achieved in patients with modular tumour endoprostheses of osteosarcoma about the knee? Clin Orthop Relat Res 2015;473:847–854.

34. Barut N, Anract P, Babinet A, Biau D. Peri-prosthetic fractures around tumor endoprostheses: a retrospective analysis of eighteen cases. Int Orthop 2015;39:1851–1856.

35. Zimmer MN, Farfalli GL, Zindman AM, et al. Revision distal femoral arthroplasty with the Compress® prosthesis has a low rate of mechanical failure at 10 years. Clin Orthop Relat Res 2016;474:528–536.

36. Goulding KA, Schwartz A, Hattrup S, et al. Use of compressive ossintegration endoprostheses for massive bone loss from tumor and failed arthroplasty: a viable option in the upper extremity. Clin Orthop Relat Res 2017;475:1702–1711.

37. Issa SP, Biau D, Babinet A, Dumaine V, Le Hanneur M, Anract P. Pelvic reconstructions following peri-acetabular bone tumour resections using a cementless ice-cream cone prosthesis with dual mobility cup. Int Orthop 2018;42:1987–1997.

38. Liang H, Ji T, Zhang Y, Wang Y, Guo W. Reconstruction with 3D-printed pelvic endoprostheses after resection of a pelvic tumour. Bone Joint J 2017;99-B:267–275.

39. Wang B, Sun P, Xie X, et al. A novel combined hemipelvic endoprosthesis for peri-acetabular tumours involving sacroiliac joint: a finite element study. Int Orthop 2015;39:2253–2259.

40. Wang B, Hao Y, Pu F, Jiang W, Shao Z. Computer-aided designed, three-dimensional-printed hemipelvic prosthesis for peri-acetabular malignant bone tumour. Int Orthop 2018;42:687–694.

41. Gilg MM, Gaston CL, Parry MC, et al. What is the morbidity of a non-invasive growing prosthesis? Bone Joint J 2016;98-B:1697–1703.

42. Arteau A, Lewis VO, Moon BS, Satcher RL, Bird JE, Lin PP. Tibial growth disturbance following distal femoral resection and expandable endoprosthetic reconstruction. J Bone Joint Surg Am 2015;97:172–178.

43. Cipriano CA, Gruzinova IS, Frank RM, Gitelis S, Virkus WW. Frequent complications and severe bone loss associated with the repiphysis expandable distal femoral prosthesis. Clin Orthop Relat Res 2015;473:831–838.

44. Schinhan M, Tiefenboeck T, Funovics P, Sevelda F, Kotz R, Windhager R. Extensible prostheses for children after resection of primary malignant bone tumor: twenty-seven years of experience. J Bone Joint Surg Am 2015;97:1585–1591.

45. Staals EL, Colangelo M, Ali N, Casanova JM, Donati DM, Manfrini M. Are complications associated with the Repiphysis® expandable distal femoral prosthesis acceptable for its continued use? Clin Orthop Relat Res 2015;473:3093–3093.
46. Torner F, Segur JM, Ullot R, et al. Non-invasive expandable prosthesis in musculoskeletal oncology pediatric patients for the distal and proximal femur: first results. *Int Orthop* 2016;40:1683–1688.

47. Campanacci L, Ali N, Casanova JM, Kreshak J, Manfrini M. Resurfaced allograft-prosthetic composite for proximal tibial reconstruction in children: intermediate-term results of an original technique. *J Bone Joint Surg Am* 2015;97:241–250.

48. Grimer RJ, Aydin BK, Wafa H, et al. Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. *Bone Joint J* 2016;98-B: 857–864.

49. Capanna R, Scoccianti G, Frenos F, Vilardi A, Beltrami G, Campanacci DA. What was the survival of megaprostheses in lower limb reconstructions after tumor resections? *Clin Orthop Relat Res* 2015;473:820–830.

50. Stevenson JD, Wigley C, Burton H, et al. Minimising aseptic loosening in extreme bone resections: custom-made tumour endoprostheses with short medullary stems and extra-cortical plates. *Bone Joint J* 2017;99-B:1689–1695.

51. Bernthal NM, Greenberg M, Heberer K, Eckardt JJ, Fowler EG. What are the functional outcomes of endoprosthetic reconstructions after tumor resection? *Clin Orthop Relat Res* 2015;473:812–819.

52. Wang B, Wu Q, Liu J, Chen S, Zhang Z, Shao Z. What are the functional results, complications, and outcomes of using a custom unipolar wrist hemiarthroplasty for treatment of Grade III giant cell tumors of the distal radius? *Clin Orthop Relat Res* 2016;474:2583–2590.

53. Benevenia J, Kirchner R, Patterson F, et al. Outcomes of a modular intercalary endoprosthesis as treatment for segmental defects of the femur, tibia, and humerus. *Clin Orthop Relat Res* 2016;474:539–548.